Oversold

GSK

Valuation39/ 100
Cash flow & growth71/ 100
Upside potential48/ 100
Risk potential27/ 100

GSK's valuation is somewhat elevated while fundamentals provide solid support and weaker than expected earnings are holding it back, though analyst coverage is limited.

Score change since last week

The score fell 6 points, mainly due to valuation and price changes. Price fell 1.8%, from $50.82 to $49.89.

Valuation and price changes subtracted 5.2 points. The comparison uses the same available inputs on both dates. Displayed changes are rounded to whole points.

Valuation

Historical cheapness: current PE is 15.1× versus the full-history median of 12.7× shown in the valuation table, producing 38.3/100. Positive weekly observations receive equal weight; lower past EPS alone does not disqualify them.

Outlook-adjusted valuation: 38.8/100. The model applies a 11.8% earnings-growth assumption and a 10% annual return hurdle, with positive credit limited by evidence coverage and confidence.

Forward price scenarios use recent PE history separately. Recent history has a separately weighted median of 15.1× (18-month half-life). The favorable scenario uses 16.1× PE and $3.9 projected EPS, informed by growth, margins and earnings-quality checks. This is a model scenario, not an analyst target. A return to the full-history median is not assumed.

Cash flow & growth

Business trends are strong. Over the past year: revenue +8.7%, earnings +45.6%. Free cash flow is 21% of revenue. The business score is 70.5/100. Growth, margins and cash generation drive the score. Missing or older data receives less weight.

Favorable scenario

Stronger earnings and valuation could support a higher share price.

Our favorable case uses $3.85 of EPS and a 16.1× PE, suggesting a share price of about $62.08. Valuation history and outlook inform the PE.

The displayed favorable scenario is 29% upside, or about $62.09.

This is a scenario based on our model, not a forecast or probability.

Downside scenario

Weaker than expected earnings could put pressure on the share price.

Our downside case uses $2.70 of EPS and a 13× PE, suggesting a share price of about $34.99 — 27% below today’s price. Valuation history and outlook inform the PE.

This is a scenario based on our model, not a forecast or probability.

GSK vs Historical averages

MetricCurrentAverageRelative
PE15x12x22% higher
PE percentile685037% higher
EPS$3.19$4.0221% lower
FCF$9.4B$8B18% higher
Loading historical comparisons…

GSK’s fundamentals are mixed relative to their historical averages, while its earnings multiple is higher.

GSK Forward outlook

MetricOutlook
Forward valuationStrongly deteriorating
Forward earningsStrong decline
Forward revenueGrowth
Forward profitability--
Analyst coverageLimited
Estimate dispersionTight

GSK’s outlook is mixed, with weaker expected earnings weighing on the picture.

GSK PE Valuation

Loading pe valuation table…

This table applies GSK's historical price-to-earnings (PE) landmarks to current earnings. The implied prices are valuation scenarios, not price forecasts or targets.

GSK Earnings Per Share

Loading earnings per share…

This chart tracks GSK's trailing twelve-month diluted earnings per share, calculated from four consecutive reported quarters to reduce seasonal noise.

GSK Quarterly Revenue

Loading quarterly revenue…

This chart tracks GSK's quarterly revenue over time and shows how sales are changing from year to year.

GSK Free Cash Flow

Loading free cash flow…

This chart tracks GSK's free cash flow over time, showing whether the business is consistently generating cash after operating costs and capital spending.

GSK Total Shares

Loading shares over time…

This chart tracks changes in GSK's diluted share count. A rising count can dilute existing owners, while a falling count often reflects share repurchases.

GSK Net Leverage

Loading net leverage…

Quarterly Net Leverage uses the last 12 months of EBITDA. A falling multiple generally indicates less debt relative to earnings capacity. Negative values mean net cash; missing data or nonpositive LTM EBITDA are N/A. The table shows each period’s Net Leverage and status.

GSK PE vs Healthcare Sector

Loading pe vs sector average…

This chart compares GSK's price-to-earnings (PE) ratio with the Healthcare sector average. A discount or premium can reflect differences in expected growth, profitability, or risk.

GSK Weekly Price

Loading weekly price…

This chart uses GSK's weekly closing prices to show the longer-term trend. The lower panes show weekly RSI and Stochastic momentum.

GSK Weekly Moving Averages

Loading weekly moving averages…

This chart compares GSK's 8, 20, 50, 100, and 200-week moving averages from 2020 onward. Shorter averages react faster to price changes, while longer averages show the broader trend.

GSK Yearly ROI

Loading yearly ROI…

Each line starts at 0% using the year’s first dependable weekly close and tracks the return through December, or through the latest available week for the current year.

UNH

Same as last week
Valuation47/ 100
Cash flow & growth46/ 100
Upside potential49/ 100
Risk potential31/ 100

UNH's valuation appears fair, fundamentals are somewhat mixed, while forward estimates point to earnings growth and improving margins.

Valuation

Historical cheapness: current PE is 24.4× versus the full-history median of 21.5× shown in the valuation table, producing 41.5/100. Positive weekly observations receive equal weight; lower past EPS alone does not disqualify them.

Outlook-adjusted valuation: 46.9/100. The model applies a 21.8% earnings-growth assumption and a 10% annual return hurdle, with positive credit limited by evidence coverage and confidence.

Forward price scenarios use recent PE history separately. Recent history has a separately weighted median of 22.4× (18-month half-life). The favorable scenario uses 24.6× PE and $20.4 projected EPS, informed by growth, margins and earnings-quality checks. This is a model scenario, not an analyst target. A return to the full-history median is not assumed.

Cash flow & growth

Business trends are mixed. Over the past year: revenue +6.5%, earnings -32.6%, operating margin -2.5 percentage points. Free cash flow is 5.2% of revenue. The business score is 45.6/100. Growth, margins and cash generation drive the score. Missing or older data receives less weight.

Favorable scenario

Stronger earnings and valuation could support a higher share price.

Our favorable case uses $20.39 of EPS and a 24.6× PE, suggesting a share price of about $500.50. Valuation history and outlook inform the PE.

The displayed favorable scenario is 32% upside, or about $500.40.

This is a scenario based on our model, not a forecast or probability.

Downside scenario

Weaker than expected earnings could put pressure on the share price.

Our downside case uses $13.45 of EPS and a 19.6× PE, suggesting a share price of about $262.95 — 31% below today’s price. Valuation history and outlook inform the PE.

This is a scenario based on our model, not a forecast or probability.

UNH vs Historical averages

MetricCurrentAverageRelative
PE24x23x8% higher
PE percentile715042% higher
EPS$15.55$18.6717% lower
FCF$23.6B$21.7B9% higher
Loading historical comparisons…

UNH’s fundamentals are mixed relative to their historical averages, while its earnings multiple is higher.

UNH Forward outlook

MetricOutlook
Forward valuationImproving
Forward earningsGrowth
Forward revenueStable
Forward profitabilityExpanding
Analyst coverageModerate
Estimate dispersionModerate

UNH’s outlook is generally improving, with growth expectations supporting the valuation case.

UNH PE Valuation

Loading pe valuation table…

This table applies UNH's historical price-to-earnings (PE) landmarks to current earnings. The implied prices are valuation scenarios, not price forecasts or targets.

UNH Earnings Per Share

Loading earnings per share…

This chart tracks UNH's trailing twelve-month diluted earnings per share, calculated from four consecutive reported quarters to reduce seasonal noise.

UNH Quarterly Revenue

Loading quarterly revenue…

This chart tracks UNH's quarterly revenue over time and shows how sales are changing from year to year.

UNH Free Cash Flow

Loading free cash flow…

This chart tracks UNH's free cash flow over time, showing whether the business is consistently generating cash after operating costs and capital spending.

UNH Total Shares

Loading shares over time…

This chart tracks changes in UNH's diluted share count. A rising count can dilute existing owners, while a falling count often reflects share repurchases.

UNH Net Leverage

Loading net leverage…

Quarterly Net Leverage uses the last 12 months of EBITDA. A falling multiple generally indicates less debt relative to earnings capacity. Negative values mean net cash; missing data or nonpositive LTM EBITDA are N/A. The table shows each period’s Net Leverage and status.

UNH PE vs Healthcare Sector

Loading pe vs sector average…

This chart compares UNH's price-to-earnings (PE) ratio with the Healthcare sector average. A discount or premium can reflect differences in expected growth, profitability, or risk.

UNH Weekly Price

Loading weekly price…

This chart uses UNH's weekly closing prices to show the longer-term trend. The lower panes show weekly RSI and Stochastic momentum.

UNH Weekly Moving Averages

Loading weekly moving averages…

This chart compares UNH's 8, 20, 50, 100, and 200-week moving averages from 2020 onward. Shorter averages react faster to price changes, while longer averages show the broader trend.

UNH Yearly ROI

Loading yearly ROI…

Each line starts at 0% using the year’s first dependable weekly close and tracks the return through December, or through the latest available week for the current year.